Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term remission and monocyclic course in Still's disease patients starting canakinumab early: data from the international AIDA network registry.

Seminars in arthritis and rheumatism·2026
Same author

Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials).

Rheumatology and therapy·2026
Same author

A field-deployable immunofluorescence chip for adenovirus monitoring in groundwater systems.

Biosensors & bioelectronics·2026
Same author

Development and validation of clinical criteria for the definition of disease activity in adult-onset Still's disease: a cohort study.

The Lancet. Rheumatology·2026
Same author

Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study.

Rheumatology and therapy·2026
Same author

Reply to comment: "Before GBS can be attributed to an infection with C. jejuni, this pathogen must be confirmed".

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026

Related Experiment Video

Updated: May 18, 2026

Antibody Profiling by Luciferase Immunoprecipitation Systems (LIPS)
12:19

Antibody Profiling by Luciferase Immunoprecipitation Systems (LIPS)

Published on: October 7, 2009

Antiphospholipid antibody profiling: time for a new technical approach?

Dirk Roggenbuck1, Karl Egerer, Philipp von Landenberg

  • 1LausitzUniversity of Applied Sciences, Senftenberg, Germany. dirk.roggenbuck@hs-lausitz.de

Autoimmunity Reviews
|September 26, 2012
PubMed
Summary

Detecting antiphospholipid antibodies for diagnosing antiphospholipid syndrome (APS) is challenging. Multiplex assays, like multi-line immunodot assays, offer a promising, cost-effective alternative to traditional ELISAs for comprehensive aPL antibody profiling.

More Related Videos

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

Related Experiment Videos

Last Updated: May 18, 2026

Antibody Profiling by Luciferase Immunoprecipitation Systems (LIPS)
12:19

Antibody Profiling by Luciferase Immunoprecipitation Systems (LIPS)

Published on: October 7, 2009

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

Area of Science:

  • Clinical Immunology
  • Laboratory Medicine
  • Diagnostic Technologies

Background:

  • Diagnosing antiphospholipid syndrome (APS) requires detecting diverse anti-phospholipid (aPL) antibodies, posing a laboratory challenge.
  • Current diagnostic criteria necessitate multiple enzyme-linked immunosorbent assays (ELISAs), increasing complexity and cost.
  • There is a need for efficient and comprehensive methods for aPL antibody profiling in APS patients.

Purpose of the Study:

  • To review novel developments in laboratory diagnostics for APS.
  • To highlight the potential of multiplex assays for simultaneous aPL antibody detection and profiling.
  • To discuss multi-line immunodot assays as a viable alternative to ELISA for APS diagnostics.

Main Methods:

  • Review of recent advancements in laboratory diagnostics for APS.
  • Focus on multiplex analysis techniques, including multi-line immunodot assays and bead-based multiplex assays.
  • Evaluation of different solid-phase reaction environments for aPL antibody assessment.

Main Results:

  • Multiplex assays offer a cost-efficient approach for detecting and profiling multiple aPL antibodies simultaneously.
  • Multi-line immunodot assays are presented as a strong alternative to ELISA for aPL antibody detection in APS.
  • Hydrophobic membranes in multi-line immunodot assays provide a unique reaction environment for aPL antibody assessment.

Conclusions:

  • Multiplex assays represent a significant advancement in the laboratory diagnosis of APS.
  • Multi-line immunodot assays show particular promise for improving the efficiency and comprehensiveness of aPL antibody profiling.
  • Further development and implementation of these novel techniques can enhance APS diagnosis and patient outcome prediction.